Annexon, Inc. (ANNX)
$5.12+$0.15 (+3.02%) TodayExtended Hours
Jamie Dananberg - OfficerAnnexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 7 | 565,000 | |
| Option exercise | 2 | 61,292 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
45 Form 4 filings on record, the earliest from Oct 2, 2024, newest first. Filing history page 2 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Muneer A. Satter | Open-market purchase | Common Stock | 400,000 | $4.48 | $1.79M | |
| Muneer A. Satter | Open-market purchase | Common Stock | 422,613 | $4.28 | $1.81M | |
| Muneer A. Satter | Open-market purchase | Common Stock | 500,000 | $2.99 | $1.50M | |
| Muneer A. Satter | Open-market purchase | Common Stock | 500,000 | $3.18 | $1.59M | |
| Muneer A. Satter | Open-market purchase | Common Stock | 500,000 | $3.94 | $1.97M | |
| William H. Carson | Open-market purchase | Common Stock | 4,115 | $3.17 | $13K | |
| William H. Carson | Open-market purchase | Common Stock | 4,115 | $3.05 | $13K | |
| William H. Carson | Open-market purchase | Common Stock | 4,115 | $2.09 | $9K | |
| William H. Carson | Open-market purchase | Common Stock | 4,115 | $2.43 | $10K | |
| Michael Overdorf - Officer | Open-market sale | Common Stock | 853 | $2.61 | $2K | |
| Ted Yednock - Officer | Open-market sale | Common Stock | 1,116 | $2.58 | $3K | |
 Jennifer Lew - Officer | Open-market sale | Common Stock | 1,117 | $2.58 | $3K | |
| William H. Carson | Open-market purchase | Common Stock | 4,115 | $2.46 | $10K | |
 Thomas G. Wiggans | Grant or award | Stock Option (Right to Buy) | 55,000 | $0.00 | - | |
| William H. Carson | Open-market purchase | Common Stock | 3,200 | $5.33 | $17K | |
| Douglas Love - Officer | Option exercise | Common Stock | 78,399 | $1.85 | $145K | |
| Douglas Love - Officer | Option exercise | Common Stock | 36,050 | $1.85 | $67K | |
| Douglas Love - Officer | Option exercise | Stock Option (Right to Buy) | 78,399 | $0.00 | - | |
| Douglas Love - Officer | Option exercise | Stock Option (Right to Buy) | 36,050 | $0.00 | - | |
| Ted Yednock - Officer | Option exercise | Common Stock | 5,408 | $1.85 | $10K | |
| Ted Yednock - Officer | Open-market sale | Common Stock | 5,408 | $7.41 | $40K | |
| Ted Yednock - Officer | Option exercise | Stock Option (Right to Buy) | 5,408 | $0.00 | - | |
| William H. Carson | Open-market purchase | Common Stock | 3,200 | $5.97 | $19K |
This is as far as the anonymous view goes. Create a free account for all 45 ANNX filings on record.
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| WIGGANS THOMAS G | Former Director | 2,000 | $11K | View on EDGAR | |
| - | - | - | - | View on EDGAR | |
| - | - | - | - | View on EDGAR |
Annexon, Inc. (ANNX) had 8 insider filings in the last 90 days, with the most recent on 2026-08-12. The full record for ANNX runs to 45 Form 4 filings, the earliest from 2024-10-02. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of ANNX were filed in the last 90 days. 18 purchases are on record for this company.
No insider sales of ANNX were filed in the last 90 days. 14 sales are on record for this company.
This page tracks ANNX Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add ANNX to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
